Post-ET Myelofibrosis Clinical Trials in Bologna
2 recruitingBologna, Italy
Showing 1–2 of 2 trials
Recruiting
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisMF+2 more
Kartos Therapeutics, Inc.600 enrolled215 locationsNCT06479135
Recruiting
Phase 1Phase 2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc.70 enrolled19 locationsNCT05280509